2024. Bimekizumab 4-year Maintenance of Responses in Week 16 Responders with Moderate to Severe Plaque Psoriasis: Results from the BE BRIGHT Open-label Extension Phase 3 Trial. SKIN The Journal of Cutaneous Medicine. 8, 6 (Nov. 2024), s437. DOI:https://doi.org/10.25251/skin.8.supp.437.